Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



There Goes Half of Arena's Market

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

In quick succession yesterday, trading in Arena Pharmaceuticals (Nasdaq: ARNA  ) was halted, the Food and Drug Administration announced the approval of its obesity drug Belviq, the company followed suit with a press release of its own, and shares resumed trading.

Those were the most important events for the company -- as witnessed by the 30% jump in the share price -- but they didn't provide the most useful information for valuing the stock. That was in the conference call that followed.

The label says that patients shouldn't stay on Belviq for longer than 12 weeks if it's clear the drug isn't working for them. According to management, 42% of patients in the pivotal clinical trials reached the 5% weight loss threshold suggested by the FDA after 12 weeks. In patients who had diabetes, the fraction responding that quickly was even lower. Just 32% of patients reached that goal.

More than half of the patients who take the drug aren't going to be on it for all that long if doctors follow the label, which is typical for a drug, at least initially. The real-world number of patients who continue after 12 weeks might actually be even lower. At least some of that weight loss is due to lifestyle changes independent of taking Belviq; we know this because patients taking placebo also lose weight. If patients in the clinical trials were more motivated to lose weight than the general population, the weight loss might be lower once the drug hits the market.

That won't be for a while. Arena and its marketing partner Eisai must wait for the Drug Enforcement Administration to rule on the schedule of the drug, which typically takes four to six months to complete. The FDA recommended that Belviq be given a Schedule IV, meaning it has some potential for abuse but that it's relatively low. If the DEA follows suit, it'll mean extra paperwork, but there won't be any restrictions around giving free samples, advertising, or setting up automatic refills of the drug. Besides the initial delay, getting reviewed by the DEA isn't that big of a deal. Teva Pharmaceuticals' (NYSE: TEVA  ) Provigil, Sanofi's (NYSE: SNY  ) Ambien, and Pfizer's (NYSE: PFE  ) Sonata are all Schedule IV dugs.

Arena will manufacture Belviq and sell the pills to Eisai for 31.5% of the net sale price, which increases to as high as 36.5% of the price for annual sales above $750 million. The initial income will have a relatively low tax rate because it's made in Switzerland, and the company negotiated a 10-year tax holiday for the plant. Arena will have to cover 10% of the cost for a post-marketing cardiovascular study and 50% of the pediatric development program.

The company wasn't willing to give the price that Eisai will sell the drug for; I guess there's no reason to tip off VIVUS (Nasdaq: VVUS  ) , which has an obesity drug that will likely be approved next month, and could launch earlier since it doesn't require DEA scheduling. But later on CNBC, CEO Jack Lief said the cost would be close to that of a Starbucks' venti latte, so figure a few dollars a day.

Ironically, cutting out a daily venti latte would cut around 275 calories and save the patient some cash to boot.

This rule-breaking multibagger has been profitable for a while. Find out the name of the company and why Fool analysts like it so much in the free report "Discover the Next Rule-Breaking Multibagger."

Fool contributor Brian Orelli holds no position in any company mentioned. Click here to see his holdings and a short bio. The Motley Fool owns shares of Starbucks. Motley Fool newsletter services have recommended buying shares of Pfizer and Starbucks and have recommended writing covered calls on Starbucks. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.

Read/Post Comments (6) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On June 28, 2012, at 2:08 PM, maccub wrote:

    did not get a schedule 4

  • Report this Comment On June 28, 2012, at 3:15 PM, JayRed wrote:

    your articles are so useless.

  • Report this Comment On June 28, 2012, at 4:16 PM, genesis667 wrote:

    Why don't you point out that the biggest market for weight loss is women ages 18-45...The same ones that will be EXCLUDED from using VVUS Qnexa due to birth defects. I guess you didn't feel the need to mention that.

  • Report this Comment On June 28, 2012, at 5:00 PM, meldog6 wrote:

    Brian again your article is based on your opion and is without merit not to smart to say the least. You mention Qnexa won't cost more than a few dollers a day about the same as a venti latte at Star Bucks. The price of a venti latte at Star Bucks is $3.57 plus tax thats over $115.00 a month. Who is going to pay [including insurance companies] when this drug combination is and has been available in generic at alot lees cost. You talk about dependency did you know as we speak ther is a trails going on in California for dependency on Phentermine to be concluded in March 2013. So again your dismal journalistic abilities still continual to shine. You are an idiot.

  • Report this Comment On June 28, 2012, at 5:15 PM, ChartMyStock wrote:
  • Report this Comment On June 28, 2012, at 5:25 PM, xtcpw wrote:

    meldog, I'm long both ARNA & VVUS. I'm sure there are all manner of reasons to criticize the author and his article, but all he did w/ the Starbucks statement was quote ARNA's CEO talking about Belviq's pricing, not Qnexa's pricing. The quote came straight from the CNBC interview w/ the ARNA CEO.

    You might want to work on your reading comprehension before you go around calling people idiots.

    And you might want to work on your spelling - it's dollars not dollers, Starbucks not Star Bucks (the name was taken from the book Moby Dick), less not lees, there not ther, and trial not trails.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1927679, ~/Articles/ArticleHandler.aspx, 10/28/2016 10:48:35 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,222.86 53.18 0.29%
S&P 500 2,138.61 5.57 0.26%
NASD 5,225.92 9.94 0.19%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/28/2016 10:32 AM
ARNA $1.52 Down -0.04 -2.56%
Arena Pharmaceutic… CAPS Rating: ***
PFE $32.23 Down -0.25 -0.77%
Pfizer CAPS Rating: ****
SNY $38.87 Up +1.62 +4.34%
Sanofi CAPS Rating: *****
TEVA $42.69 Down -0.46 -1.07%
Teva Pharmaceutica… CAPS Rating: ****
VVUS $1.09 Down -0.02 -1.80%
VIVUS CAPS Rating: **